Protocol Number: INV-DEN-104; A Randomized, Phase 1b Study to Investigate the Safety and Immunogenicty of Various Schedules of Tetravalent Chimeric Dengue Vaccine in Healthy Adult Volunteers Between the Ages of 18-45 Years

Project: Other project

StatusFinished
Effective start/end date12/20/119/1/15

Funding

  • Takeda Vaccines Inc: $465,571.16